O	0	3	The
O	4	13	influence
O	14	16	of
O	17	20	the
O	21	31	initiation
O	32	34	of
O	35	37	an
B-intervention	38	46	exercise
O	47	56	programme
O	57	59	on
B-condition	60	66	seroma
I-condition	67	76	formation
I-condition	77	80	and
I-condition	81	91	dehiscence
O	92	101	following
O	102	108	breast
O	109	115	cancer
O	116	123	surgery
O	123	124	.

O	125	127	To
O	128	134	verify
O	135	142	whether
O	143	148	early
O	149	150	(
O	150	155	first
O	156	160	post
O	160	161	-
O	161	170	operative
O	171	174	day
O	174	175	)
O	176	178	or
O	179	183	late
O	184	194	initiation
O	195	196	(
O	196	201	after
O	202	209	removal
O	210	212	of
O	213	216	the
O	217	227	continuous
O	228	235	suction
O	236	241	drain
O	241	242	)
O	243	245	of
O	246	247	a
O	248	258	functional
O	259	273	rehabilitation
O	274	282	exercise
O	283	292	programme
O	293	303	influences
O	304	307	the
O	308	317	incidence
O	318	320	of
O	321	327	seroma
O	328	337	formation
O	338	341	and
O	342	352	dehiscence
O	353	356	for
B-eligibility	357	362	women
I-eligibility	363	368	after
I-eligibility	369	375	breast
I-eligibility	376	382	cancer
I-eligibility	383	390	surgery
O	390	391	.

O	392	400	Benefits
O	401	403	of
O	404	409	early
O	410	424	implementation
O	425	427	of
O	428	430	an
O	431	439	exercise
O	440	449	programme
O	450	459	initiated
O	460	464	with
O	465	470	women
O	471	473	in
O	474	477	the
O	478	483	first
O	484	488	days
O	489	498	following
O	499	505	breast
O	506	512	cancer
O	513	520	surgery
O	521	524	are
O	525	531	widely
O	532	537	known
O	537	538	.

O	539	546	However
O	546	547	,
O	548	551	the
O	552	556	safe
O	557	567	initiation
O	568	570	of
O	571	574	the
O	575	584	exercises
O	585	587	is
O	588	593	still
O	594	595	a
O	596	609	controversial
O	610	615	issue
O	616	619	and
O	620	624	some
O	625	632	authors
O	633	642	correlate
O	643	648	early
O	649	659	initiation
O	660	662	of
O	663	666	the
O	667	676	exercises
O	677	681	with
O	682	684	an
O	685	693	increase
O	694	696	in
O	697	703	seroma
O	704	713	formation
O	713	714	.

O	715	716	A
O	717	728	prospective
O	728	729	,
O	730	740	randomised
O	740	741	,
O	742	752	controlled
O	753	761	clinical
O	762	767	trial
O	767	768	.

B-total-participants	769	776	Seventy
I-total-participants	776	777	-
I-total-participants	777	782	seven
O	783	788	women
O	789	793	were
O	794	802	randomly
O	803	811	assigned
O	812	814	to
O	815	823	initiate
O	824	827	the
O	828	837	programme
O	838	840	on
O	841	845	post
O	845	846	-
O	846	855	operative
O	856	859	day
O	860	861	1
O	862	863	(
O	863	868	early
O	869	874	group
O	875	876	=
B-intervention-participants	877	879	40
O	879	880	)
O	881	883	or
O	884	889	after
O	890	897	removal
O	898	900	of
O	901	904	the
O	905	910	drain
O	911	912	(
B-control	912	916	late
I-control	917	922	group
O	923	924	=
B-control-participants	925	927	37
O	927	928	)
O	929	932	and
O	933	937	were
O	938	947	monitored
O	948	953	until
O	954	957	the
O	958	962	45th
O	963	967	post
O	967	968	-
O	968	977	operative
O	978	981	day
O	981	982	.

O	983	991	Patients
O	992	994	in
O	995	998	the
O	999	1004	early
O	1005	1010	group
O	1011	1015	were
O	1016	1026	instructed
O	1027	1029	to
O	1030	1037	perform
O	1038	1041	the
O	1042	1051	exercises
O	1052	1057	daily
O	1058	1060	at
O	1061	1065	home
O	1065	1066	,
O	1067	1076	beginning
O	1077	1079	on
O	1080	1084	post
O	1084	1085	-
O	1085	1094	operative
O	1095	1098	day
O	1099	1100	1
O	1100	1101	,
O	1102	1107	while
O	1108	1113	those
O	1114	1116	of
O	1117	1120	the
O	1121	1125	late
O	1126	1131	group
O	1132	1137	began
O	1138	1141	the
O	1142	1151	exercises
O	1152	1157	after
O	1158	1161	the
O	1162	1167	drain
O	1168	1171	was
O	1172	1179	removed
O	1179	1180	.

O	1181	1184	The
O	1185	1195	assessment
O	1196	1199	for
O	1200	1206	seroma
O	1207	1216	formation
O	1217	1220	and
O	1221	1231	dehiscence
O	1232	1235	was
O	1236	1245	performed
O	1246	1248	on
O	1249	1253	post
O	1253	1254	-
O	1254	1263	operative
O	1264	1268	days
O	1269	1270	7
O	1271	1274	and
O	1275	1277	45
O	1277	1278	.

O	1279	1284	There
O	1285	1288	was
O	1289	1291	no
O	1292	1305	statistically
O	1306	1317	significant
O	1318	1328	difference
O	1329	1335	regard
O	1336	1338	to
B-outcome	1339	1345	seroma
I-outcome	1346	1355	formation
O	1356	1363	between
O	1364	1369	early
O	1370	1375	group
O	1376	1379	and
O	1380	1384	late
O	1385	1390	group
O	1390	1391	.

O	1392	1396	Also
O	1397	1402	there
O	1403	1406	was
O	1407	1409	no
O	1410	1421	association
O	1422	1429	between
O	1430	1433	the
B-outcome	1434	1442	presence
I-outcome	1443	1445	of
I-outcome	1446	1456	dehiscence
O	1457	1460	and
O	1461	1466	early
O	1467	1476	exercises
O	1476	1477	.

O	1478	1481	The
O	1482	1487	early
O	1488	1498	initiation
O	1499	1501	of
O	1502	1505	the
O	1506	1515	exercises
O	1516	1519	for
O	1520	1525	women
O	1525	1526	,
O	1527	1536	following
O	1537	1543	breast
O	1544	1550	cancer
O	1551	1558	surgery
O	1558	1559	,
O	1560	1571	constitutes
O	1572	1573	a
O	1574	1578	safe
O	1579	1587	practice
O	1588	1591	for
O	1592	1595	the
O	1596	1610	rehabilitation
O	1610	1611	.

O	1612	1619	However
O	1619	1620	,
O	1621	1626	these
O	1627	1635	findings
O	1636	1640	need
O	1641	1643	to
O	1644	1646	be
O	1647	1654	further
O	1655	1663	explored
O	1664	1667	and
O	1668	1677	confirmed
O	1678	1680	in
O	1681	1682	a
O	1683	1689	larger
O	1690	1696	sample
O	1696	1697	.

O	1698	1705	Studies
O	1706	1713	showing
O	1714	1722	evidence
O	1723	1727	that
O	1728	1733	early
O	1734	1744	functional
O	1745	1759	rehabilitation
O	1760	1767	process
O	1768	1770	is
O	1771	1772	a
O	1773	1777	safe
O	1778	1786	practice
O	1787	1790	for
O	1791	1796	women
O	1797	1803	having
O	1804	1811	surgery
O	1812	1815	for
O	1816	1822	breast
O	1823	1829	cancer
O	1829	1830	,
O	1831	1833	as
O	1834	1838	well
O	1839	1841	as
O	1842	1845	the
O	1846	1853	present
O	1854	1862	research
O	1862	1863	,
O	1864	1867	are
O	1868	1870	of
O	1871	1879	interest
O	1880	1882	to
O	1883	1889	health
O	1890	1903	professionals
O	1904	1907	who
O	1908	1912	care
O	1913	1916	for
O	1917	1922	these
O	1923	1931	patients
O	1932	1935	and
O	1936	1946	contribute
O	1947	1949	to
O	1950	1953	the
O	1954	1959	wider
O	1960	1966	global
O	1967	1975	clinical
O	1976	1985	community
O	1985	1986	.
